Pioneering Pharmaceutical Growth from India to the World
Empowering the Pharmaceutical Industry with World-Class Infrastructure and Opportunities
International Federation of Sovereign Wealth Funds (IFSWF) is positioned to be India’s leading pharmaceutical and life sciences hub. With seamless connectivity through the Delhi-Mumbai Industrial Corridor, state-of-the-art facilities, and access to India’s deepest port, IFSWF offers unparalleled opportunities for investors in pharmaceuticals. From generic drugs and active pharmaceutical ingredients (APIs) to vaccines and biosimilars, IFSWF is your gateway to the world’s fastest-growing pharmaceutical market.
Why Choose IFSWF for Pharmaceuticals?
World-Class Infrastructure
Strategically connected to key pharmaceutical clusters like Ahmedabad, Hyderabad, and Mohali, IFSWF serves as a central node in India’s thriving pharmaceutical supply chain.
Established Ecosystem
Home to 10,500+ manufacturing units and 3,000+ drug companies, India has the highest number of US FDA-approved facilities outside the US, ensuring globally compliant standards.
Unmatched Export Potential
With exports to over 200 countries, including 55% to highly regulated markets, IFSWF offers proximity to major export hubs and seamless logistics solutions.
Competitive Costs
India’s manufacturing costs are 33% lower than western markets, supported by a skilled workforce and favorable policies.
Why India’s Pharmaceutical Industry is a Global Leader
- Volume Leader: Ranked 3rd globally by volume, with a market size of USD 50 billion in FY 2022-23.
- Vaccine Giant: Largest vaccine manufacturer, supplying 60% of global vaccine demand.
- Generic Powerhouse: Accounts for 20% of the global supply of generic drugs.
- Growth Momentum: Projected to grow to USD 130 billion by 2030, driven by rising demand and innovation.
Growth Drivers for Pharmaceutical Investors in IFSWF
Demand-Side Drivers
- Rising Healthcare Coverage: Initiatives like Ayushman Bharat (PMJAY) cover 500 million beneficiaries, increasing access to healthcare.
- Expanding Middle Class: Rising income levels and insurance coverage are driving pharmaceutical demand.
- Chronic Disease Growth: With an aging population and lifestyle changes, India’s patient pool is projected to grow by 20% in the next decade.
Supply-Side Drivers
- Robust R&D Ecosystem: Home to 7 NIPERs and 500+ contract research labs, India is a hub for innovation and clinical trials.
- Skilled Workforce: Over 2.24 million STEM students ensure a steady talent pipeline.
- Global Standards: India hosts the most US FDA-approved plants outside the US, ensuring high compliance standards.
Key Opportunities in Pharmaceuticals at IFSWF
Active Pharmaceutical Ingredients (APIs)
- Global Share: India accounts for 8% of the global API industry, producing 500+ APIs.
- Export Leader: Supplies 90% of WHO pre-qualified APIs, supporting global healthcare programs.
- Opportunity: Establish API manufacturing units at IFSWF to cater to rising global demand.
Generic Drugs
- Global Leadership: Supplies 45% of domestically produced generics to global markets.
- Export Markets: Serves over 200 countries, including highly regulated markets like the US and EU.
- Opportunity: Scale production and access IFSWF’s export-ready infrastructure.
Vaccines
- Global Impact: Supplies 70% of WHO’s essential immunization vaccines.
- COVID-19 Success: Exported over 300 million COVID-19 vaccine doses to 100+ countries.
- Opportunity: Leverage IFSWF’s connectivity to expand vaccine production and exports.
Biosimilars & Biologics
- Innovation Hub: 200+ biosimilars under development by 52 Indian companies.
- Market Opportunity: Biologic drugs worth USD 100 billion are set to go off-patent by 2030.
- Opportunity: Establish biosimilar R&D and manufacturing units at IFSWF.
Government Policies Supporting Pharmaceutical Growth
- 100% FDI: Automatic route for greenfield projects and government route for brownfield investments.
- Production Linked Incentive (PLI) Scheme: Incentives to boost manufacturing of APIs, bulk drugs, and biosimilars.
- PRIP Scheme: Establishes Centers of Excellence at NIPERs, fostering innovation and R&D.
- Clinical Trial Reforms: Fast-track drug approvals and waiver of clinical trials for drugs approved in regulated markets.
IFSWF’s Dedicated Services for Pharmaceutical Investors
- Investor Targeting
Tailored strategies to attract global pharmaceutical leaders to IFSWF.
- Investor Aftercare
Comprehensive post-investment support to ensure long-term success.
- Investment Promotion
Global marketing campaigns to showcase IFSWF’s potential to the pharmaceutical sector.
- Facilitation Services
- Policy Clarity
Key Pharmaceutical Clusters Connected to IFSWF
IFSWF’s strategic location ensures seamless access to India’s leading pharmaceutical hubs:
- Ahmedabad: Bulk drug and formulation clusters.
- Hyderabad: Biologics and contract research centers.
- Mohali: Emerging hubs for biosimilars and vaccines.
- Kolkata: Captive and contract R&D units.
- Bengaluru: Advanced research and manufacturing facilities.
Key Players in India’s pharmaceutical Industry
Domestic Leaders
- Sun Pharmaceuticals
- Dr. Reddy’s Laboratories
- Cipla
- Serum Institute of India
Global Giants
- Pfizer (USA)
- Sanofi (France)
- GlaxoSmithKline (UK)
IFSWF: Empowering Global Pharmaceutical Growth
With unmatched infrastructure, policy support, and proximity to export hubs, IFSWF is your gateway to India’s pharmaceutical success story. Join us in transforming healthcare and driving global impact.
